A carregar...
Publicação
Innervis: launching a startup to commercialize central nervous system targeted antiviral therapies- strategic and operational development and intellectual property protection strategies
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 862.43 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Neurotropic viruses like Zika, Dengue, HIV, and SARS-CoV-2 infiltrate the central nervous system, causing irreversible brain damage and congenital defects. Nevertheless, current antivirals have limited effectiveness in crossing the blood-brain barrier. Innervis, under an
exclusive license from the Gulbenkian Institute for Molecular Medicine (GiMM), develops Peptide-Porphyrin Conjugates (PPCs) that overcome these barriers and neutralize viruses in neural tissue. This business plan outlines the strategy to establish a pipeline into the drug
development market, covering IP creation, operational execution, potential partnerships, funding needs and sources, and valuation scenarios that build a clear roadmap to a pharmaceutical acquisition.
Descrição
Palavras-chave
Strategy Entrepreneurship Intrapreneurship International business M&A Venture capital Fund raising Technology strategy Intellectual property Operations management Startup Biotech Therapeutics market Management Financials Cost structure Operations Valuation Exit strategy Funding